SLC9A6, solute carrier family 9 member A6, 10479

N. diseases: 210; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Mental Retardation, X-Linked, Syndromic, Christianson Type
0.800 GeneticVariation disease BEFREE Of the genes in that region, we propose that SLC9A6 is the most likely to play an important role as mutations in this gene lead to Christianson syndrome, in which patients may have microcephaly and weight loss. 31583675 2020
CUI: C0025958
Disease: Microcephaly
Microcephaly
0.440 GeneticVariation disease BEFREE Of the genes in that region, we propose that SLC9A6 is the most likely to play an important role as mutations in this gene lead to Christianson syndrome, in which patients may have microcephaly and weight loss. 31583675 2020
CUI: C0004610
Disease: Bacteremia
Bacteremia
0.100 Biomarker disease BEFREE DCS re-sensitised MRSA to β-lactams in vitro and significantly enhanced MRSA eradication by oxacillin in a mouse bacteraemia model. 31628459 2020
CUI: C0004610
Disease: Bacteremia
Bacteremia
0.100 Biomarker disease BEFREE We collected 59 MRSA isolates from adult patients with bacteremia. 31721291 2020
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.100 Biomarker disease BEFREE These results suggest that tedizolid represents a promising therapeutic option for the treatment of CF-associated MRSA/MSSA infections, having potent in vivo activity and low resistance potential. 31617901 2020
CUI: C0149778
Disease: Soft Tissue Infection
Soft Tissue Infection
0.100 Biomarker group BEFREE Nose and throat carriage of MRSA and PVL-SA was low among recruits, despite a high incidence of SSTIs being reported, particularly cellulitis. 31357012 2020
MRSA - Methicillin resistant Staphylococcus aureus infection
0.100 Biomarker disease BEFREE This review focuses on the clinical significance of MRSA infections and new approaches for the laboratory diagnosis and epidemiologic typing of MRSA strains. 31523762 2020
MRSA - Methicillin resistant Staphylococcus aureus infection
0.100 Biomarker disease BEFREE Currently, this organism's ability in developing resistance to antibiotics is notorious; methicillin-resistant Staphylococcus aureus-MRSA-is known for its resistance to methicillin, oxacillin, and others. 31667799 2020
CUI: C0264515
Disease: Pneumonia, Necrotizing
Pneumonia, Necrotizing
0.050 Biomarker disease BEFREE We found that passive immunization with either a monoclonal antibody (mAb) neutralizing alpha-hemolysin or a broadly cross-reactive mAb that neutralize Panton-Valentine leukocidin, leukocidin ED and gamma-hemolysins HlgAB/HlgCB only conferred partial protection, whereas the combination of those two mAbs conferred significant protection in a rabbit model of necrotizing pneumonia caused by the USA300 MRSA epidemic clone. 31844012 2020
CUI: C4552483
Disease: ABSSSI
ABSSSI
0.040 Biomarker disease BEFREE Levonadifloxacin displayed potent activity against contemporary MRSA and fluoroquinolone-resistant staphylococcal isolates, thus offering a valuable IV as well as an oral therapeutic option for the treatment of ABSSSIs. 31840170 2020
CUI: C0744130
Disease: Diabetic foot infection
Diabetic foot infection
0.020 Biomarker disease BEFREE For this S. aureus strains (MSSA and MRSA) were isolated from patients with diabetic foot infection. 31313350 2020
CUI: C0702166
Disease: Acne
Acne
0.010 GeneticVariation disease BEFREE Whole genome sequencing and mass spectrometry of the purified peptide confirmed that <i>S. capitis</i> APC2923 produces a 3458 Da bacteriocin, designated nisin J, which exhibited antimicrobial activity against a range of Gram-positive pathogens including MRSA and <i>Cutibacterium acnes.</i> The gene order in the nisin J gene cluster (<i>nsjFEGBTCJP</i>) differs from those of other nisin variants, in that it is lacking the nisin regulatory genes, <i>nisRK</i>, as well as the nisin immunity gene, <i>nisI</i> Nisin J has 9 amino acid changes when compared to prototypical nisin A; 8 amino acid substitutions, 6 of which are not present in other nisin variants (Ile4Lys, Met17Gln, Gly18Thr, Asn20Phe, Met21Ala, Ile30Gly, Val33His and Lys34Thr) and an extra amino acid close to the C-terminus, rendering nisin J the only nisin variant to contain 35 amino acids. 31740495 2020
Mental Retardation, X-Linked, Syndromic, Christianson Type
0.800 Biomarker disease BEFREE Collectively, these findings expand our understanding of the genetic diversity of CS and further elucidate a critical role for SLC9A6/NHE6 in fine-tuning recycling endosomal pH and cargo trafficking, processes crucial for the maintenance of neuronal polarity and mature synaptic structures. 30296617 2019
Mental Retardation, X-Linked, Syndromic, Christianson Type
0.800 GeneticVariation disease BEFREE A Christianson syndrome-linked deletion mutation (Δ287ES288) in SLC9A6 impairs hippocampal neuronal plasticity. 31175985 2019
Mental Retardation, X-Linked, Syndromic, Christianson Type
0.800 Biomarker disease BEFREE Our findings establish the Slc9a6 KO mouse as a relevant tool for studying the sensory deficits in CS, and highlight selective vulnerabilities in relevant cell populations that may contribute to this phenotype. 29772390 2019
CUI: C0004610
Disease: Bacteremia
Bacteremia
0.100 Biomarker disease BEFREE Univariate analysis revealed that infection was more frequent in patients with MRSA-carriage (p < 0.001), in case of previous catheter-related infection (p < 0.05) and of bacteremia or bacteriuria in the period of 3 months before catheter implantation (p < 0.001). 31151433 2019
CUI: C0004610
Disease: Bacteremia
Bacteremia
0.100 Biomarker disease BEFREE We found a high incidence of E faecium and a low incidence of MRSA and Pseudomonas bacteremias following ASCT in our patient population. 30689291 2019
CUI: C0004610
Disease: Bacteremia
Bacteremia
0.100 Biomarker disease BEFREE Thirty-day readmission rate was 22% (SE, 0.3) overall with no difference between MRSA and MSSA, but MRSA bacteremia had more readmission for bacteremia recurrence (hazard ratio, 1.17 [95% confidence interval {CI}, 1.02-1.34]), higher in-hospital mortality (odds ratio, 1.15 [95% CI, 1.07-1.23]), and longer hospitalization (incidence rate ratio, 1.09 [95% CI, 1.06-1.11]). 30753447 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.100 Biomarker disease BEFREE Duplicate isolates from the same site and year and those obtained for MRSA surveillance or from patients with cystic fibrosis were excluded. 30753206 2019
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.100 Biomarker disease BEFREE MRSA and Trichosporon) along with B. contaminans ST102 might have contributed to the worsening of clinical conditions in our CF patients. 31464603 2019
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.100 Biomarker disease BEFREE The main goal of this study was to evaluate PK/pharmacodynamic (PKPD) target attainment when using a 600 mg intravenous q12h linezolid dose against MRSA in obese patients with pneumonia. 30535122 2019
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.100 Biomarker disease BEFREE However, little is known about the role of IL-17 in CA-MRSA pneumonia. 30026066 2019
CUI: C0032285
Disease: Pneumonia
Pneumonia
0.100 GeneticVariation disease BEFREE More patients with qSOFA ≥2 had altered mentation (23% vs 5%, p < 0.0001), were infected with MRSA (42% vs 30%, p = 0.03), had endocarditis or pneumonia (29% vs 15%, p = 0.0028), and bacterial persistence ≥4d (34% vs 20%, p = 0.0039) compared to qSOFA <2 patients. 30760213 2019
CUI: C0037278
Disease: Skin Diseases, Infectious
Skin Diseases, Infectious
0.100 Biomarker group BEFREE Coupled to a low cytotoxic activity, we believe our lead compound can be developed into a topical antibacterial agent to replace mupirocin as the first-line drug for treating MRSA skin infections. 30103288 2019
CUI: C0149778
Disease: Soft Tissue Infection
Soft Tissue Infection
0.100 GeneticVariation group BEFREE To overcome the increasing difficulties in the clinical management of SSTI due to MRSA, new prophylactic and therapeutic approaches are urgently needed and a preventive vaccine would be welcome. 31299217 2019